2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport rock-bottom valuations right now. With the Fed possibly set to reverse course on interest rates next year,…#federalreserve #agenus #coherusbiosciences #chrs #fda #crc #bms #udenyca #neulasta #cimerli (Source: Reuters: Health)
Source: Reuters: Health - December 24, 2023 Category: Consumer Health News Source Type: news
FDA OKs New Agent to Block Chemotherapy-Induced Neutropenia FDA OKs New Agent to Block Chemotherapy-Induced Neutropenia
The new colony-stimulating factor from China proved comparable to pegfilgrastim (Neulasta) in clinical testing.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
5 Dirt-Cheap Healthcare Stocks With Big Dividends To Buy Now
While many Wall Street firms are suggesting short Treasury paper and money markets now, for long-term investors looking for growth and income, healthcare is the place to be for the rest of 2023 and likely 2024. Demand is growing as the country ages; pricing remains solid and plain and…#treasury #amgen #amgeninc #neulasta #prolia #xgeva #otezla #behcet #aranesp #kyprolis (Source: Reuters: Health)
Source: Reuters: Health - November 11, 2023 Category: Consumer Health News Source Type: news
FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma FDA OKs Motixafortide for Stem Cell Mobilization in Myeloma
The GENESIS trial reported substantially better stem cell mobilization when patients with multiple myeloma received motixafortide alongside filgrastim.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 11, 2023 Category: Transplant Surgery Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Aphexda (motixafortide) to Mobilize Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma
Aphexda is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade
One dosage of Aphexda plus filgrastim enabled a majority of patients to achieve the collection goal of≥ 6 million... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 11, 2023 Category: Drugs & Pharmacology Source Type: news
Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myeloma
(MedPage Today) -- The FDA has approved the CXCR4 antagonist motixafortide (Aphexda) for use with filgrastim (Neupogen) to mobilize stem cells for autologous transplantation in multiple myeloma, BioLineRx announced on Monday.
Recent advances in... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - September 11, 2023 Category: Surgery Source Type: news
Earnings Results: Amgen stock jumps after record earnings beat expectations, and biotech raises full-year outlook
Shares of Amgen Inc. jumped in after-hours trading Thursday, after the biotechnology giant reported record second-quarter earnings that rose above expectations and raised the full-year outlook, as volume growth offset a slight decline in prices. “We had a very strong quarter, serving more patients…#amgeninc #robertbradway #amgn #prolia #aranesp #parsabiv #neulasta #eps (Source: Reuters: Health)
Source: Reuters: Health - August 3, 2023 Category: Consumer Health News Source Type: news
NPPA fixes retail price of 74 drug formulations
The NPPA said it has also revised the ceiling price of 80 scheduled formulations (NLEM 2022) including the one to treat epilepsy and neutropenia. The ceiling price of one tablet (200mg) of Sodium Valproate has been fixed at Rs 3.20. Similarly, the ceiling price of Filgrastim injection (one vial) has been fixed at Rs 1,034.51. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Stimufend (pegfilgrastim-fpgk), a Biosimilar to Neulasta
September 6, 2022 -- Fresenius Kabi, a global health care company that specializes in pharmaceuticals, medical technologies, and nutrition products for critical and chronic conditions, announced today that the United States (U.S.) Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 6, 2022 Category: Drugs & Pharmacology Source Type: news
FDA Approves Fylnetra (pegfilgrastim-pbbk), a Biosimilar to Neulasta
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- May 27, 2022 -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the“Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 27, 2022 Category: Drugs & Pharmacology Source Type: news
Releuko (Filgrastim-ayow Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 3, 2022 Category: Drugs & Pharmacology Source Type: news
Oncology Care Model Reduces Cost of Supportive Care Meds Oncology Care Model Reduces Cost of Supportive Care Meds
The Oncology Care Model led to notable reductions in the use of the pricy monoclonal antibody denosumab, more rapid adoption of the biosimilar filgrastim, and more selective use of costly antiemetics.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA Approves Releuko (filgrastim-ayow), a Biosimilar to Neupogen
February 28, 2022 -- The United States (U.S.) Food and Drug Administration (FDA) has approved Releuko (filgrastim-ayow), a biosimilar to Neupogen (filgrastim).
The FDA approval was based on a review of data that demonstrated a high degree of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2022 Category: Drugs & Pharmacology Source Type: news
Drug maker Lupin inks licensing pact with Axantia for Pegfilgrastim
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Lupin had earlier received the USFDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 1, 2022 Category: Pharmaceuticals Source Type: news
Drug maker Lupin inks licensing pact with Axantia for Pegfilgrastim
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy. Lupin had earlier received the USFDA acceptance for review of the Biologics License Application (BLA) for its proposed biosimilar to Neulasta (pegfilgrastim). (Source: The Economic Times)
Source: The Economic Times - February 1, 2022 Category: Consumer Health News Source Type: news
